Breast Cancer

Watch our video to learn more about the Xilis MOSTM platform and how it selects the optimal therapy choice for each individual patient.

Publications and Abstract Index Utilizing MOSTM Technology

Title: Micro-organospheres: an automated patient-derived model platform for rapid drug screening of breast cancer.

We have now shown the feasibility of establishing micro-organospheres as a rapid, scalable, and cost-effective platform to study patient-derived BC drug response.

Breast Cancer

In the United States, breast cancer is the most common cancer in women, other than skin cancer. It is the second leading cause of cancer death in women, with the average risk of developing breast cancer at 13%. Triple-negative breast cancer, an aggressive form, accounts for 15% of all breast cancers.1 Xilis is utilizing its MicroOrganoSphereTM technology to evaluate its potential as an automated platform for cancer drug screening. Below is a list of our recent presentations.

American Cancer Society:
Accessed September 2021.